Journal article

The combination of reduced MCL-1 and standard chemotherapeutics is tolerable in mice

Kerstin Brinkmann, Stephanie Grabow, Craig D Hyland, Charis E Teh, Warren S Alexander, Marco J Herold, Andreas Strasser

Cell Death & Differentiation | NATURE PUBLISHING GROUP | Published : 2017

Grants

Awarded by NHMRC


Awarded by NHMRC Independent Research Institutes Infrastructure Support Scheme Grant


Awarded by LLS SCOR grant


Awarded by CCV grant


Funding Acknowledgements

We thank K Hughes, C D'Alessandro, K McKenzie, T Krtson, C Gatt and G Siciliano for expert animal care; B Helbert and K Mackwell for genotyping; J Corbin and J McManus for automated blood analysis; E Tsui, V Orlando, K Weston, Y Hoang, C Tsui, S Ter for help with histology, S Monard and his team for help with flow cytometry and P Bouillet for providing Mcl-1<SUP>+/-</SUP> mice and helping with histology assessment, D Grey for his advice for the intracellular FACS analysis of BCL-2 family members and for providing the relevant antibodies and staining solutions. This work was supported by grants and fellowships from the Deutsche Krebshilfe (Dr. Milded-Scheel-post-doctoral fellowship to KB) NHMRC feliowship (1020363), NHMRC program grant (1016701), LLS SCOR grant (7001-13) and CCV grant (1052309) (all to AS). Cancer Council Victoria Venture Grant and Victorian Cancer Agency (VCATRP13041) (to MJH) NHMRC Feliowship (1058344), NHMRC Program Grant (1113577), NHMRC Independent Research Institutes Infrastructure Support Scheme Grant (361646), the Australian Cancer Research Fund and Victorian State Government Operational Infrastructure Support (all to WSA),